BioAge Labs, Inc. SEC filings BIOA
BioAge Labs, Inc. has 155 filings in SEC EDGAR's recent list, going back to Feb 13, 2024. Its latest annual report, Form ARS, was filed on Apr 21, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 5, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 2, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 2, 2026 | Oct 2, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 4 | Insider transaction | Jul 1, 2026 | Jun 29, 2026 |
| 144 | Notice of proposed sale | Jun 30, 2026 | — |
| 144 | Notice of proposed sale | Jun 29, 2026 | — |
| 4 | Insider transaction | Jun 12, 2026 | Jun 10, 2026 |
| 4 | Insider transaction | Jun 12, 2026 | Jun 10, 2026 |
| 4 | Insider transaction | Jun 12, 2026 | Jun 10, 2026 |
| 4 | Insider transaction | Jun 12, 2026 | Jun 10, 2026 |
| 4 | Insider transaction | Jun 12, 2026 | Jun 10, 2026 |
| 4 | Insider transaction | Jun 12, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2026 | Jun 10, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| 8-K |
Current report
Results of operations
|
May 8, 2026 | May 8, 2026 |
| 10-Q | Quarterly report | May 8, 2026 | Mar 31, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Apr 27, 2026 | — |
| 4 | Insider transaction | Apr 24, 2026 | Apr 23, 2026 |
| ARS | Annual report to shareholders | Apr 21, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 21, 2026 | — |
| DEF 14A | Proxy statement | Apr 21, 2026 | Jun 10, 2026 |
| 4 | Insider transaction | Apr 3, 2026 | Apr 1, 2026 |
| 144 | Notice of proposed sale | Apr 1, 2026 | — |
| S-3ASR | Automatic shelf registration | Mar 24, 2026 | — |
| S-8 | Employee stock plan registration | Mar 24, 2026 | — |
| 10-K | Annual report | Mar 24, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 24, 2026 | Mar 24, 2026 |
| 4 | Insider transaction | Mar 3, 2026 | Mar 2, 2026 |
| 4 | Insider transaction | Mar 3, 2026 | Mar 1, 2026 |
| 144 | Notice of proposed sale | Mar 2, 2026 | — |
| 4 | Insider transaction | Feb 19, 2026 | Feb 17, 2026 |
| 4 | Insider transaction | Feb 19, 2026 | Feb 17, 2026 |
| 4 | Insider transaction | Feb 19, 2026 | Feb 17, 2026 |
| 4 | Insider transaction | Feb 19, 2026 | Feb 17, 2026 |
| 4 | Insider transaction | Feb 19, 2026 | Feb 17, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 13, 2026 | — |
| 4 | Insider transaction | Feb 3, 2026 | Feb 2, 2026 |
| 4 | Insider transaction | Feb 3, 2026 | Feb 1, 2026 |
| 144 | Notice of proposed sale | Feb 2, 2026 | — |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jan 22, 2026 | Jan 21, 2026 |
| 424B5 | Prospectus supplement | Jan 22, 2026 | — |
| 4 | Insider transaction | Jan 21, 2026 | Jan 16, 2026 |
| 424B5 | Prospectus supplement | Jan 20, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 20, 2026 | Jan 20, 2026 |
| 4 | Insider transaction | Jan 15, 2026 | Jan 13, 2026 |
| 4 | Insider transaction | Jan 15, 2026 | Jan 13, 2026 |
| 144 | Notice of proposed sale | Jan 13, 2026 | — |
| 144 | Notice of proposed sale | Jan 13, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 12, 2026 | Jan 12, 2026 |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| 144 | Notice of proposed sale | Jan 2, 2026 | — |
| 4 | Insider transaction | Dec 11, 2025 | Dec 9, 2025 |
| 144 | Notice of proposed sale | Dec 9, 2025 | — |
| 4 | Insider transaction | Dec 5, 2025 | Dec 4, 2025 |
| 144 | Notice of proposed sale | Dec 4, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 4, 2025 | Dec 4, 2025 |
| 10-Q | Quarterly report | Nov 6, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| S-3/A | Filing | Nov 5, 2025 | — |
| S-3/A | Filing | Nov 5, 2025 | — |
| S-3 | Shelf registration | Oct 2, 2025 | — |
| S-3 | Shelf registration | Oct 2, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2025 | — |
| 4 | Insider transaction | Aug 11, 2025 | Aug 7, 2025 |
| 10-Q | Quarterly report | Aug 6, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2025 | Aug 6, 2025 |
| 4 | Insider transaction | Jun 9, 2025 | Jun 5, 2025 |
| 4 | Insider transaction | Jun 9, 2025 | Jun 5, 2025 |
| 4 | Insider transaction | Jun 9, 2025 | Jun 5, 2025 |
| 4 | Insider transaction | Jun 9, 2025 | Jun 5, 2025 |
| 4 | Insider transaction | Jun 9, 2025 | Jun 5, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2025 | Jun 5, 2025 |
| 8-K |
Current report
Other events
|
Jun 4, 2025 | Jun 4, 2025 |
| 10-Q | Quarterly report | May 6, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 6, 2025 | May 6, 2025 |
| ARS | Annual report to shareholders | Apr 17, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 17, 2025 | — |
| DEF 14A | Proxy statement | Apr 17, 2025 | Jun 5, 2025 |
| S-8 | Employee stock plan registration | Mar 20, 2025 | — |
| 10-K | Annual report | Mar 20, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 20, 2025 | Mar 20, 2025 |
| 4/A | Filing | Mar 10, 2025 | Apr 17, 2024 |
| 4 | Insider transaction | Mar 10, 2025 | Sep 27, 2024 |
| 4/A | Filing | Feb 25, 2025 | Feb 18, 2025 |
| 4 | Insider transaction | Feb 20, 2025 | Feb 18, 2025 |
| 4 | Insider transaction | Feb 20, 2025 | Feb 18, 2025 |
| 4 | Insider transaction | Feb 20, 2025 | Feb 18, 2025 |
| 4 | Insider transaction | Feb 20, 2025 | Feb 18, 2025 |
| 4 | Insider transaction | Feb 20, 2025 | Feb 18, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 14, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 14, 2025 | — |
| 4 | Insider transaction | Dec 20, 2024 | Dec 18, 2024 |
| SC 13G | Ownership over 5% (passive) | Nov 14, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Nov 12, 2024 | — |
| 10-Q | Quarterly report | Nov 7, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2024 | Nov 7, 2024 |
| SC 13G | Ownership over 5% (passive) | Oct 7, 2024 | — |
| SC 13D | Ownership over 5% (active) | Oct 4, 2024 | — |
| 4 | Insider transaction | Oct 3, 2024 | Oct 1, 2024 |
| 4 | Insider transaction | Oct 1, 2024 | Sep 27, 2024 |
| SC 13D | Ownership over 5% (active) | Sep 30, 2024 | — |
| 4 | Insider transaction | Sep 27, 2024 | Sep 27, 2024 |
| 4 | Insider transaction | Sep 27, 2024 | Sep 25, 2024 |
| 4 | Insider transaction | Sep 27, 2024 | Apr 17, 2024 |
| 4 | Insider transaction | Sep 27, 2024 | Sep 25, 2024 |
| 4 | Insider transaction | Sep 27, 2024 | Apr 17, 2024 |
| 4 | Insider transaction | Sep 27, 2024 | Mar 26, 2024 |
| 4 | Insider transaction | Sep 27, 2024 | Aug 19, 2024 |
| 4 | Insider transaction | Sep 27, 2024 | Apr 17, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 27, 2024 | Sep 25, 2024 |
| S-8 | Employee stock plan registration | Sep 26, 2024 | — |
| 424B4 | Prospectus | Sep 26, 2024 | — |
| SEC STAFF LETTER | Filing | Sep 25, 2024 | — |
| EFFECT | Filing | Sep 25, 2024 | — |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| S-1MEF | Filing | Sep 25, 2024 | — |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| 3 | Initial insider ownership | Sep 25, 2024 | Sep 25, 2024 |
| CERT | Filing | Sep 25, 2024 | — |
| CORRESP | Letter to the SEC | Sep 25, 2024 | — |
| S-1/A | Amended registration statement | Sep 25, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 23, 2024 | — |
| CORRESP | Letter to the SEC | Sep 23, 2024 | — |
| CORRESP | Letter to the SEC | Sep 23, 2024 | — |
| CORRESP | Letter to the SEC | Sep 18, 2024 | — |
| 8-A12B | Filing | Sep 18, 2024 | — |
| S-1/A | Amended registration statement | Sep 18, 2024 | — |
| CORRESP | Letter to the SEC | Sep 12, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 6, 2024 | — |
| CORRESP | Letter to the SEC | Sep 3, 2024 | — |
| S-1 | Registration statement | Sep 3, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 9, 2024 | — |
| DRSLTR | Filing | Aug 5, 2024 | — |
| DRS/A | Filing | Aug 5, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 18, 2024 | — |
| DRSLTR | Filing | Jul 3, 2024 | — |
| DRS/A | Filing | Jul 3, 2024 | — |
| SEC STAFF LETTER | Filing | Jun 28, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 28, 2024 | — |
| DRS | Filing | May 31, 2024 | — |
| D | Filing | Feb 13, 2024 | — |
Showing 155 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BIOA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Emeryville, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1709941
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.